Related Experiment Video
Updated: May 16, 2026
Adoptive Transfer of IL-33-Stimulated Macrophages into Bleomycin-Induced Mouse Models to Study Their Effect on Idiopathic Pulmonary Fibrosis In Vivo
Published on: May 5, 2023
Nerandomilast attenuates Pantoea agglomerans-induced hypersensitivity pneumonitis by regulating M1 macrophage
Yujie Shi1,2, Yuming Liu3, Zhigang Liu3
1Department of Pulmonary and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No. 1 Shuaifuyuan Street, Dongcheng District, Beijing, 100730, China.
Background:
Hypersensitivity pneumonitis (HP) is characterized by bronchiolocentric inflammation and fibrosis. The characteristic pathological features include bronchiolocentric inflammation, peribronchiolar fibrosis, and the presence of poorly formed granulomas. Nerandomilast is a novel oral phosphodiesterase 4 (PDE4) inhibitor with good selectivity for PDE4B. PDE4 inhibitors (PDE4i) exhibit anti-inflammatory/antifibrotic properties, the efficacy of nerandomilast remains unexplored in HP.
Methods:
We selected macrophages and fibroblasts as effector cells for the inflammatory and fibrotic phases of HP in vitro. And we established in vivo HP models induced by saline extract of the cells of P. agglomerans (SE-PA).
Results:
The results of the in vitro studies revealed that nerandomilast inhibited the expression of proinflammatory markers (i.e., CD86, iNOS, and IL-1β) of M1 macrophages by increasing CREB phosphorylation and inhibiting the NF-κB signaling pathway. Furthermore, nerandomilast reduced TGFβ1-induced fibroblast activation by inhibiting Smad and non-Smad signaling pathways. In vivo studies confirmed that nerandomilast could reduce the number of inflammatory cells in bronchoalveolar lavage fluid and the secretion of proinflammatory cytokines (such as IL-1β, IL-6, and TNF-α), lower the serum levels of the oxidative stress markers MPO and MDA, and inhibit the transcription of proinflammatory cytokines in lung tissue. Moreover, nerandomilast alleviated pulmonary fibrosis and pulmonary dysfunction in mice with HP induced by SE-PA.
Conclusion:
Our findings indicated that nerandomilast might attenuate inflammation and fibrosis in SE-PA-induced HP mice by regulating macrophage polarization and inhibiting fibroblast activation, which provides new insights for the clinical treatment of HP.
